https://www.selleckchem.com/pr....oducts/auranofin.htm
The purpose of this study was to determine the efficacy of nanoparticle-encapsulated Fidgetin-like 2 (FL2) siRNA (FL2-NPsi), a novel therapeutic agent targeting the gene, for the treatment of corneal alkaline chemical injury. Eighty 12-week-old, male Sprague-Dawley rats were divided evenly into 8 treatment groups prednisolone, empty nanoparticles, control-NPsi (1 µM, 10 µM, and 20 µM) and FL2-NPsi (1 µM, 10 µM, and 20 µM). An alkaline burn was induced onto the cornea of each rat, which was then treated for 14 days according to group a
Curtir
Comentario
Compartilhar
